search
Back to results

Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>

Primary Purpose

Leukemia

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
cyclophosphamide
methotrexate
peripheral blood stem cell transplantation
radiation therapy
Sponsored by
Fred Hutchinson Cancer Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia focused on measuring recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent adult acute myeloid leukemia, recurrent adult acute lymphoblastic leukemia, adult acute lymphoblastic leukemia in remission, childhood acute lymphoblastic leukemia in remission, acute undifferentiated leukemia, secondary acute myeloid leukemia

Eligibility Criteria

undefined - 55 Years (Child, Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: One of the following diagnoses: Primary acute leukemia beyond first remission High-risk acute myelogenous leukemia Acute lymphoblastic leukemia in first remission Must have HLA-matched donor identical for HLA-A, -B, and DRB1 alleles No HLA-matched identical sibling or haploidentical relative incompatible for 0 or 1 HLA-A, -B, or -DRB1 loci on the non-shared haplotype No leukoencephalopathy PATIENT CHARACTERISTICS: Age: 55 and under Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: SGOT no greater than 2 times normal Hepatitis B surface antigen negative No prior hepatitis C Renal: No impaired renal function Creatinine less than 2 times normal Cardiovascular: No symptomatic cardiac disease Pulmonary: No active pulmonary disease DLCO at least 60% predicted Other: HIV negative No disease or other malignancy that severely limits life expectancy No severe or life-threatening infection within the past 2 weeks No history of septate fungal infection or disseminated candidiasis PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow or peripheral blood stem cell transplantation Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy greater than 3,000 cGy to whole brain No prior radiotherapy of 1,500 cGy to chest or abdomen At least 6 months since prior involved-field radiotherapy to chest or abdomen Surgery: Not specified

Sites / Locations

  • Fred Hutchinson Cancer Research Center

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
October 11, 2001
Last Updated
May 12, 2010
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00025545
Brief Title
Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>
Official Title
A Phase II Trial to Evaluate the Use of G-CSF-Mobilized Peripheral Blood Progenitor Cells as Hematopoietic Rescue in Patients With Acute Leukemia Undergoing Allografting From an Unrelated Donor
Study Type
Interventional

2. Study Status

Record Verification Date
May 2010
Overall Recruitment Status
Completed
Study Start Date
March 1996 (undefined)
Primary Completion Date
October 2002 (Actual)
Study Completion Date
October 2002 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary
RATIONALE: Transplanted peripheral stem cells can sometimes be rejected by the body's tissues. Treating donor peripheral stem cells with filgrastim may increase the number of donor white blood cells. This may help to decrease the rejection of the transplanted cells in patients receiving them as treatment for acute leukemia. PURPOSE: Phase II trial to study the effectiveness of filgrastim-treated donor peripheral stem cells in treating patients with acute leukemia who are undergoing peripheral stem cell transplantation.
Detailed Description
OBJECTIVES: Determine whether filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation reduces the incidence of non-leukemic mortality in patients with acute leukemia. Determine the kinetics and durability of engraftment after treatment with this regimen in these patients. Determine the incidence and severity of acute and chronic graft-versus-host disease in patients treated with this regimen. Determine the leukemia-free survival of patients treated with this regimen. OUTLINE: Donors receive filgrastim (G-CSF) subcutaneously (SC) on days -5 to -1. Donors then undergo leukapheresis on days -1 and 0. Patients undergo total body irradiation twice daily on days -7 to -4. Patients receive 2 doses of intrathecal methotrexate per local guidelines between days -10 and -3. Patients also receive cyclophosphamide IV on days -3 and -2. Patients receive infusion of allogeneic peripheral blood stem cells on day 0. PROJECTED ACCRUAL: A total of 5-60 patients will be accrued for this study within 3 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia
Keywords
recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent adult acute myeloid leukemia, recurrent adult acute lymphoblastic leukemia, adult acute lymphoblastic leukemia in remission, childhood acute lymphoblastic leukemia in remission, acute undifferentiated leukemia, secondary acute myeloid leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Masking
None (Open Label)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
cyclophosphamide
Intervention Type
Drug
Intervention Name(s)
methotrexate
Intervention Type
Procedure
Intervention Name(s)
peripheral blood stem cell transplantation
Intervention Type
Radiation
Intervention Name(s)
radiation therapy

10. Eligibility

Sex
All
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: One of the following diagnoses: Primary acute leukemia beyond first remission High-risk acute myelogenous leukemia Acute lymphoblastic leukemia in first remission Must have HLA-matched donor identical for HLA-A, -B, and DRB1 alleles No HLA-matched identical sibling or haploidentical relative incompatible for 0 or 1 HLA-A, -B, or -DRB1 loci on the non-shared haplotype No leukoencephalopathy PATIENT CHARACTERISTICS: Age: 55 and under Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: SGOT no greater than 2 times normal Hepatitis B surface antigen negative No prior hepatitis C Renal: No impaired renal function Creatinine less than 2 times normal Cardiovascular: No symptomatic cardiac disease Pulmonary: No active pulmonary disease DLCO at least 60% predicted Other: HIV negative No disease or other malignancy that severely limits life expectancy No severe or life-threatening infection within the past 2 weeks No history of septate fungal infection or disseminated candidiasis PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow or peripheral blood stem cell transplantation Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy greater than 3,000 cGy to whole brain No prior radiotherapy of 1,500 cGy to chest or abdomen At least 6 months since prior involved-field radiotherapy to chest or abdomen Surgery: Not specified
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claudio Anasetti, MD
Organizational Affiliation
Fred Hutchinson Cancer Center
Official's Role
Study Chair
Facility Information:
Facility Name
Fred Hutchinson Cancer Research Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109-1024
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>

We'll reach out to this number within 24 hrs